Trastuzumab – CRI Report

Investigation Report on China’s Trastuzumab Market 2021-2025

admin — Fri, 23 Apr 2021 13:03:01 +0000

Trastuzumab is a monoclonal antibody used to treat breast cancer and stomach cancer, and is especially used for the treatment of certain HER-2 positive cancers. The original drug, HERCEPTIN was developed by Roche’s subsidiary corporation. In 2002, Trastuzumab entered the Chinese market. Currently, besides Roche, the other main manufacturer in the Chinese market is Shanghai Henlius Biotech, Inc.
According to CRI’s market research, the sales revenue of Trastuzumab in the Chinese market has an accelerated increase from 2016 to 2019. In 2020, the sales value of Trastuzumab in China was approximately CNY1.52 billion, which decreased 22.5% YoY. The CAGR of sales value of Trastuzumab in China is about 19.8% in 2016 to 2020. CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Trastuzumab will have a recovery growth from 2021 to 2025.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Trastuzumab will have a recovery growth from 2021 to 2025. In addition, the sales of Trastuzumab will also increase due to the price reduction and market expansion. Since Trastuzumab entered the Chinese market, its price has had a decreasing trend. For example, Roche’s HERCEPTIN’s price has dropped from CNY24,500 to CNY5,500. CRI predicts that with the launch of biosimilar drugs, the price of Trastuzumab may keep falling, which will lead to an increase in sales. Moreover, as the detection of HER-2 for gastric cancer continues to be promoted, Trastuzumab will have larger market penetration in the treatment of gastric cancer in the future.

Topics Covered:
-The impact of COVID-19 on China’s Trastuzumab market
– Sales value and volume of China’s Trastuzumab 2016-2020
– Competitive landscape of China’s Trastuzumab market
– Prices of Trastuzumab in China
– Prices of Trastuzumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Trastuzumab market
– Prospect of China’s Trastuzumab market from 2021 to 2025

The post Investigation Report on China’s Trastuzumab Market 2021-2025 first appeared on CRI Report.

Sample of Investigation Report on Trastuzumab in China, 2018-2022

admin — Fri, 04 Jan 2019 06:33:32 +0000

This is a free sample of

Investigation Report on Trastuzumab in China, 2018-2022

The post Sample of Investigation Report on Trastuzumab in China, 2018-2022 first appeared on CRI Report.

Investigation Report on Trastuzumab in China, 2018-2022

admin — Fri, 17 Aug 2018 09:05:11 +0000

New Report on This Topic:

Investigation Report on China’s Trastuzumab Market 2021-2025

Trastuzumab Market

Trastuzumab was developed by GENEGENTECH and approved in Sept. 1998 by the FDA for clinical use. Its trade name is Herceptin and it is now a major product of Roche. In 2017, trastuzumab was sold for around USD 7 billion worldwide. It is a standard medicine recommended by the international medical community for HER2 positive breast cancer and gastric cancer.

In 2002, trastuzumab entered the Chinese market and was mainly used to treat HER2 metastatic breast cancer. After entering China, trastuzumab developed rapidly. Its annual sales increased from less than CNY 70 million in 2007 to CNY 887 million in 2017, and the CAGR reached 30.4% during 2007 to 2017. Before 2017, trastuzumab was produced by GENENTECH and Roche. Since 2017, it has been monopolized by the latter in the Chinese market. Currently, Roche is the single product in the market

Trastuzumab was first approved to market by the FDA in Sept. 1998 and was admitted to China in 2002. The patent for trastuzumab in the EU expired in Jul. 2014 and will expire in the U.S. in Jun. 2019. Many pharmaceutical companies have taken part in the research and development of biosimilar drugs. Three biomedical companies, Fuhong Hanlin, Anke Bio and Jiahe Bio, are now producing biosimilar of Trastuzumab in clinical Phase III.

According to the approval requirements of CDE, Fuhong Hanlin and Anke Bio are expected to be the first to hold licenses. Fuhong Hanlin is even ahead of the other and is expected to get sales permits in 2019, which makes it the first case of domestic biosimilar of trastuzumab.

In Jul. 2017, Trastuzumab was incorporated in China’s National Health Insurance Directory, which caused a surge in market demand and shortages in many parts of the country. In Jun. 2018, the CFDA issued a notice to allow Trastuzumab be sold on market when being inspected through ports, which can save 2 to 3 months.

CRI expects that from 2018 to 2020 Roche’s Herceptin will continue to monopolize the Chinese market. In 2020, domestic trastuzumab will be successively launched and grab market shares at a low price. Besides, the incidence of breast cancer and gastric diseases in China keeps rising, so the demand for trastuzumab will also continue to increase.

Topics Covered
Development environment of Trastuzumab
Development of Trastuzumab in China
Chinese Market Size of Trastuzumab
Sale Price of Trastuzumab in China
Competition Landscape of Trastuzumab in China
Prospects of Chinese trastuzumab market

The post Investigation Report on Trastuzumab in China, 2018-2022 first appeared on CRI Report.